Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

987 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status.
Ferrer E, Curto J, Esteve A, Miro JM, Tural C, Murillas J, Segura F, Barrufet P, Casabona J, Podzamczer D; PISCIS Investigators. Ferrer E, et al. Among authors: miro jm. J Antimicrob Chemother. 2015 Dec;70(12):3332-8. doi: 10.1093/jac/dkv272. Epub 2015 Sep 25. J Antimicrob Chemother. 2015. PMID: 26410171
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J. Podzamczer D, et al. Among authors: miro jm. Antivir Ther. 2002 Jun;7(2):81-90. Antivir Ther. 2002. PMID: 12212928 Clinical Trial.
Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.
Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. Plana M, et al. Among authors: miro jm. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):791-9. doi: 10.1097/00126334-200407010-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15213562
Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption.
Florence E, García F, Plana M, Fumero E, Castro P, Lopez A, Cruceta A, Gil C, Arnedo M, Miró JM, Pumarola T, Gallart T, Gatell JM. Florence E, et al. Among authors: miro jm. Clin Infect Dis. 2004 Aug 15;39(4):569-74. doi: 10.1086/422720. Epub 2004 Aug 3. Clin Infect Dis. 2004. PMID: 15356824
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].
Iribarren JA, Labarga P, Rubio R, Berenguer J, Miró JM, Antela A, González J, Moreno S, Arrizabalaga J, Chamorro L, Clotet B, Gatell JM, López-Aldeguer J, Martínez E, Polo R, Tuset M, Viciana P, Santamaría JM, Kindelán JM, Ribera E, Segura F; Grupo de Estudio de Sida; Consejo Asesor Clínico del Plan Nacional sobre el Sida del Ministerio de Sanidad y Consumo. Iribarren JA, et al. Among authors: miro jm. Enferm Infecc Microbiol Clin. 2004 Dec;22(10):564-642. doi: 10.1157/13069520. Enferm Infecc Microbiol Clin. 2004. PMID: 15596051 Spanish.
[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection].
Laguno M, Sánchez-Tapias JM, Murillas J, Forns X, Blanco JL, Martínez E, Larrousse M, León A, Loncá M, Milinkovic A, Miró JM, García F, Gatell JM, Mallolas J. Laguno M, et al. Among authors: miro jm. Enferm Infecc Microbiol Clin. 2005 Jan;23(1):32-40. doi: 10.1157/13070408. Enferm Infecc Microbiol Clin. 2005. PMID: 15701331 Review. Spanish.
987 results